Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment

Yu-Shan Chang; Ying-Tin Chen; Tso-Ting Lai; Hung-Chieh Chou; Chien-Yi Chen; Wu-Shiun Hsieh; Chung-May Yang; Po-Ting Yeh; Po-Nien Tsao

doi:10.1371/journal.pone.0223972

Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment

PLoS One. 2019 Oct 16;14(10):e0223972. doi: 10.1371/journal.pone.0223972. eCollection 2019.

Authors

Yu-Shan Chang¹, Ying-Tin Chen², Tso-Ting Lai³, Hung-Chieh Chou⁴, Chien-Yi Chen⁴, Wu-Shiun Hsieh⁴, Chung-May Yang³, Po-Ting Yeh³, Po-Nien Tsao^{4

5}

Affiliations

¹ Department of Pediatrics, National Cheng Kung University Hospital, Tainan, Taiwan.
² Department of Pediatrics, China Medical University Children's Hospital, Taichung, Taiwan.
³ Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan.
⁴ Department of Pediatrics, National Taiwan University Children's Hospital, Taipei, Taiwan.
⁵ The Research Center for Developmental Biology and Regenerative Medicine, National Taiwan University, Taipei, Taiwan.

Abstract

This single-centered, retrospective cohort study investigated the timing of involution of retinopathy of prematurity (ROP) and retinal vascularization to zone III after intravitreal bevacizumab (IVB) treatment and its possible impacts on postnatal growth and neurodevelopment. Premature infants with birth weight ≤1500 g, born between 2008 to 2014 and diagnosed with ROP were enrolled. All patients with type 1 ROP underwent IVB as 1st line treatment and were recruited as the study group; those with any stage of ROP except type 1 ROP without treatment served as controls. Neurodevelopmental outcomes were assessed using the Bayley Score of Infant Development (BSID) editions II or III. The study group included 35 eyes from 18 patients; the control group included 86 patients. Twenty-three eyes (65.7%) exhibited ROP regression after a single dose of IVB. The majority of plus sign and extraretinal neovascularization regressed within two weeks. The length of time for retinal vascularization to reach zone III was significantly longer in the treatment group compared with the control (mean post-menstruation age 54.5 vs. 47.0 weeks, p<0.001). Long-term follow-up showed no significant differences in body weight and neurodevelopment between the study and control groups up to the 2-year corrected age.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Angiogenesis Inhibitors / administration & dosage*
Angiogenesis Inhibitors / therapeutic use
Bevacizumab / administration & dosage*
Bevacizumab / therapeutic use
Body Weight
Case-Control Studies
Female
Humans
Infant
Infant, Newborn
Intravitreal Injections
Male
Retinal Neovascularization / drug therapy*
Retinopathy of Prematurity / drug therapy*
Retrospective Studies
Treatment Outcome

Substances

Angiogenesis Inhibitors
Bevacizumab

Grants and funding

This work was supported by National Taiwan University Children Hospital (grant number NTUH.106-P01) to Dr. PTN. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.